BlossomHill Therapeutics Q2 EPS $(8.75)

BlossomHill Therapeutics (NASDAQ: BLSM) reported a Q2 loss of $(8.75) per share, which represents a 58.8% increase in losses compared to $(5.51) per share in the same quarter last year.